Healthcare
Nkarta, Inc.(NKTX)
Live Price
Offline$2.86
+3.62% today
1Y Change
+62.36%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $210.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +11.9%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nkarta, Inc. (NKTX) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $2.86 and up 62.4% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +11.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +11.9%, free cash flow +13.6% with operating margin 0.0% and ROIC -31.4%. Stock Foundry combines NKTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +11.9%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -8.2% | -8.5% | -9.8% |
2026 Mar 25, 2026 | -15.6% | +0.5% | +2.8% | +39.9% |
2025 Nov 10, 2025 | +9.4% | +2.6% | -7.7% | -3.1% |
Benchmark Edge
NKTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NKTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NKTX Max Drawdown
-34.22%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NKTX and SPY.
Company Overview
Nkarta, Inc.
NASDAQ Global Select
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- Leadership
- Paul J. Hastings
- IPO Date
- Jul 10, 2020
- Employees
- 157
- Street Address
- 6000 Shoreline Court
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 582 4923
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.7
Growth
- Revenue
- 0.0%
- EPS
- +11.9%
- Free Cash Flow
- +13.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -30.0%
- ROIC
- -31.4%
Balance Sheet
- Debt/Equity
- 0.24
- Current Ratio
- 12.69
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.